Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals Inc (NQ: RYTM )

39.87 -2.88 (-6.74%)
Streaming Delayed Price Updated: 11:40 AM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
U.S. Markets Open Higher; Dow Rises Around 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Friday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning! We're entering the final day of trading for the week with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Rhythm Pharma Secures Non-Dilutive Financing Of $100M To Use Of This...
Via Benzinga
21 Stocks Moving in Friday's Pre-Market Session
Gainers Athersys, Inc. (NASDAQ: ATHX) rose 48.5% to $0.4755 in pre-market trading after dropping more than 12% on Thursday. 
Via Benzinga
Expert Ratings for Rhythm Pharmaceuticals
Analysts have provided the following ratings for Rhythm Pharmaceuticals (NASDAQ:RYTM) within the last quarter: 
Via Benzinga
Rhythm Pharmaceuticals: Q1 Earnings Insights
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q1 earnings results on Tuesday, May 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 34.4% to $2.81 during Thursday's after-market session. The market value of their outstanding shares is at $29.0 million. 
Via Benzinga
Rhythm Pharmaceuticals' Shares Dive Following FDA's Verdict On IMCIVREE Drug
The U.S. Food and Drug Administration (FDA) has approved Rhythm Pharmaceuticals’ (NASDAQ: RYTM) supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R)... 
Via Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
5 Biotech Stocks To Watch During The Week Of June 13
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
30 Stocks Moving in Monday's Pre-Market Session
Gainers G Medical Innovations Holdings Ltd (NASDAQ: GMVD) rose 53.6% to $0.5301 in pre-market trading after dropping more than 28% on Friday. 
Via Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
3 Stocks to Buy the Dip Now
You've heard the adage "buy the dip," but not all dips are made equal. There are several strategies for finding worthwhile discounted stocks. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 351 stocks hit new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Rhythm Pharmaceuticals Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET
Rhythm Pharmaceuticals (NASDAQ:RYTM) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Rhythm Pharmaceuticals (RYTM) Conference Call Follow... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into... 
Via Benzinga
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 32.4% to $7.43 during Wednesday's regular session. Sunshine Biopharma's stock is trading at a volume of 46.8... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares jumped 77.7% to $3.5950. Advent Technologies and Hyundai Motor Company entered into technology assessment, sales... 
Via Benzinga
Rhythm Pharma Shares Fall After Modifications To Setmelanotide Trials In Rare Diseases of Obesity
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM)  
Via Benzinga
Rhythm Pharmaceuticals Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q4 sales of $1.82 million. Earnings fell to a loss of $42.87 million, resulting in a 22.1% decrease from last... 
Via Benzinga
Rhythm Pharmaceuticals: Q4 Earnings Insights
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Thinking About Buying Stock In Lucid Group, Rhythm Pharmaceuticals Or Kohl's?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.